DBV Technologies Balance Sheet Health
Financial Health criteria checks 4/6
DBV Technologies has a total shareholder equity of $54.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $93.1M and $39.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$46.44m |
| Equity | US$54.03m |
| Total liabilities | US$39.02m |
| Total assets | US$93.06m |
Recent financial health updates
Recent updates
FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial
Sep 21DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M
Aug 01DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty
Jul 07DBV Technologies reports change in U.S. reporting status, cuts headcount
Jan 07DBV Technologies CSO Hugh Sampson to step down from role
Nov 24DBV Technologies shares rockets 85% as EMA approves Viaskin Peanut application
Nov 02Financial Position Analysis
Short Term Liabilities: DBVT's short term assets ($68.8M) exceed its short term liabilities ($30.9M).
Long Term Liabilities: DBVT's short term assets ($68.8M) exceed its long term liabilities ($8.1M).
Debt to Equity History and Analysis
Debt Level: DBVT is debt free.
Reducing Debt: DBVT has no debt compared to 5 years ago when its debt to equity ratio was 1.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DBVT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: DBVT has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.7% each year.